Fresh analysis indicates that people who come off blockbuster slimming jabs like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who halt conventional lifestyle regimens.
Research printed in a leading medical journal shows that while overweight individuals frequently drop about a fifth of their total mass while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month once they quit.
"People purchasing these medications need to be aware of the potential of quick rebound weight gain when the treatment concludes," cautioned expert Dr. Susan Jebb.
Such speed of regain suggests a return to pre-treatment weight within about a year and a half.
Weighing Treatments
The analysis, which looked at dozens of trials involving over 9,000 of patients, contrasted the results of GLP-1 agonists with other pills.
The team point out that people who shed pounds through dieting typically experience a more gradual creep back—approximately 0.1 kg a month—after stopping.
Explaining the Fast Regain
Doctors propose the mode of action of the injections is key to understanding the accelerated rebound.
GLP-1 drugs imitate a body's own chemical called GLP-1, which controls hunger.
"Long-term administration of GLP-1 levels far above than the body's typical production might result in the body to generate a reduced amount of its endogenous GLP-1, and could reduce responsiveness to its effects," said Dr. Adam Collins, a dietetics expert.
"Withdrawal of this hormone supplement means appetite is no longer kept in check, making excessive eating far more likely."
A Lifelong Issue?
Medical guidelines suggest the jabs for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
Professionals say that, due to the significant potential of relapse, the therapy should be considered life-long.
This perspective is reinforced by drug manufacturers, who say that the findings "highlight the persistent character of obesity," akin to managing diseases like high blood pressure.
User Experiences
People who have discontinued the medication report a powerful return of hunger.
"I experienced something flipping and I was suddenly ravenous," said one woman.
The struggle is compounded if patients have not adopted permanent lifestyle or habit changes during therapy.
Widespread Use
Survey data show that millions of adults in the UK have used these injections in the past year, with interest being substantial.
- Adoption is greater among females compared to men.
- The middle-aged demographic shows the highest usage rates.
- A large proportion access the drugs through private healthcare rather than the NHS.
In conclusion, experts stress that while GLP-1 drugs are effective tools for weight loss, they are not a permanent cure and lasting health benefits relies on integrated behavioural changes.
